Skip to main content
SpringerLink
Log in

Motor fluctuations and Helicobacter pylori in Parkinson’s disease

  • Original Communication
  • Published:
Journal of Neurology Aims and scope Submit manuscript

Abstract

The presence of Helicobacter pylori (HP) in the gastrointestinal tract may limit the absorption of levodopa. The objectives of this study were to investigate whether HP infection may affect the clinical response to levodopa as well as levodopa dose requirement in patients with Parkinson’s disease (PD) as well as to investigate whether HP infection may affect plasma levels of vitamin B12, folic acid, and homocysteine. Seventy-five patients with PD diagnosed at least 4 years ago were included. Symptom fluctuations were assessed by UPDRS-IV and the WOQ9 wearing-off-scale. Plasma levels of vitamin B12, folic acid, and homocysteine were analyzed. Screening for HP was performed with a 13C-labeled urea breath test (Diabact UBT). A propensity-matched analysis was made where each patient in the HP-infected group was matched with one patient in the non-infected group with respect to age and gender. Of the 75 included patients, 20 were HP infected (27 %). Median Hoehn & Yahr scores were 3 in both HP infected patients and the matched group (n = 20). HP-infected patients had decreased “complications of therapy” with average total UPDRS-IV score of 4.8 ± 3.0 vs. 7.7 ± 3.8 (p < 0.05), despite no significant difference in levodopa equivalent dose. Wearing-off and sleep disturbance were significantly less common in the HP group (p < 0.05). There were no differences regarding vitamin B12, folic acid, or homocysteine values. HP infection in patients with PD may result in a decreased occurrence of symptom fluctuations according to this small study. This finding may be due to altered absorption of levodopa in the gastrointestinal tract in patients with HP infection, but further studies are required.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Lewitt PA (2008) Levodopa for the treatment of Parkinson’s disease. N Engl J Med 359(23):2468–2476. doi:10.1056/NEJMct0800326

    Article  PubMed  CAS  Google Scholar 

  2. Nyholm D, Lennernas H (2008) Irregular gastrointestinal drug absorption in Parkinson’s disease. Expert Opin Drug Metab Toxicol 4(2):193–203. doi:10.1517/17425255.4.2.193

    Article  PubMed  CAS  Google Scholar 

  3. Nyholm D, Karlsson E, Lundberg M, Askmark H (2010) Large differences in levodopa dose requirement in Parkinson’s disease: men use higher doses than women. Eur J Neurol 17(2):260–266. doi:10.1111/j.1468-1331.2009.02866.x

    Article  PubMed  CAS  Google Scholar 

  4. Pierantozzi M, Pietroiusti A, Brusa L, Galati S, Stefani A, Lunardi G, Fedele E, Sancesario G, Bernardi G, Bergamaschi A, Magrini A, Stanzione P, Galante A (2006) Helicobacter pylori eradication and l-dopa absorption in patients with PD and motor fluctuations. Neurology 66(12):1824–1829. doi:10.1212/01.wnl.0000221672.01272.ba

    Article  PubMed  CAS  Google Scholar 

  5. Niehues M, Hensel A (2009) In-vitro interaction of l-dopa with bacterial adhesins of Helicobacter pylori: an explanation for clinical differences in bioavailability? J Pharm Pharmacol 61(10):1303–1307. doi:10.1211/jpp/61.10.0005

    PubMed  CAS  Google Scholar 

  6. Fiddian-Green RG (2007) Helicobacter pylori eradication and l-dopa absorption in patients with PD and motor fluctuations. Neurology 68(13):1085. doi:10.1212/01.wnl.0000260440.07107.99 author reply 1085

    Article  PubMed  Google Scholar 

  7. Lyte M (2010) Microbial endocrinology as a basis for improved L-DOPA bioavailability in Parkinson’s patients treated for Helicobacter pylori. Med Hypotheses 74(5):895–897. doi:10.1016/j.mehy.2009.11.001

    Article  PubMed  CAS  Google Scholar 

  8. Nielsen HH, Qiu J, Friis S, Wermuth L, Ritz B (2012) Treatment for Helicobacter pylori infection and risk of Parkinson’s disease in Denmark. Eur J Neurol 19(6):864–869. doi:10.1111/j.1468-1331.2011.03643.x

    Article  PubMed  CAS  Google Scholar 

  9. Lacy BE, Rosemore J (2001) Helicobacter pylori: ulcers and more: the beginning of an era. J Nutr 131(10):2789S–2793S

    PubMed  CAS  Google Scholar 

  10. Brown LM (2000) Helicobacter pylori: epidemiology and routes of transmission. Epidemiol Rev 22(2):283–297

    Article  PubMed  CAS  Google Scholar 

  11. Pounder RE, Ng D (1995) The prevalence of Helicobacter pylori infection in different countries. Aliment Pharmacol Ther 9(Suppl 2):33–39

    PubMed  Google Scholar 

  12. Storskrubb T, Aro P, Ronkainen J, Sipponen P, Nyhlin H, Talley NJ, Engstrand L, Stolte M, Vieth M, Walker M, Agreus L (2008) Serum biomarkers provide an accurate method for diagnosis of atrophic gastritis in a general population: the Kalixanda study. Scand J Gastroenterol 43(12):1448–1455. doi:10.1080/00365520802273025

    Article  PubMed  CAS  Google Scholar 

  13. Graham DY, Adam E, Reddy GT, Agarwal JP, Agarwal R, Evans DJ Jr, Malaty HM, Evans DG (1991) Seroepidemiology of Helicobacter pylori infection in India. Comparison of developing and developed countries. Dig Dis Sci 36(8):1084–1088

    Article  PubMed  CAS  Google Scholar 

  14. Graham DY, Lew GM, Klein PD, Evans DG, Evans DJ Jr, Saeed ZA, Malaty HM (1992) Effect of treatment of Helicobacter pylori infection on the long-term recurrence of gastric or duodenal ulcer. A randomized, controlled study. Ann Intern Med 116(9):705–708

    Article  PubMed  CAS  Google Scholar 

  15. Kusters JG, van Vliet AH, Kuipers EJ (2006) Pathogenesis of Helicobacter pylori infection. Clin Microbiol Rev 19(3):449–490. doi:10.1128/CMR.00054-05

    Article  PubMed  CAS  Google Scholar 

  16. Lehours P, Yilmaz O (2007) Epidemiology of Helicobacter pylori infection. Helicobacter 12(Suppl 1):1–3. doi:10.1111/j.1523-5378.2007.00541.x

    Article  PubMed  Google Scholar 

  17. Malaty HM (2007) Epidemiology of Helicobacter pylori infection. Best Pract Res Clin Gastroenterol 21(2):205–214. doi:10.1016/j.bpg.2006.10.005

    Article  PubMed  Google Scholar 

  18. Xia HH, Talley NJ (1997) Natural acquisition and spontaneous elimination of Helicobacter pylori infection: clinical implications. Am J Gastroenterol 92(10):1780–1787

    PubMed  CAS  Google Scholar 

  19. Roosendaal R, Kuipers EJ, Buitenwerf J, van Uffelen C, Meuwissen SG, van Kamp GJ, Vandenbroucke-Grauls CM (1997) Helicobacter pylori and the birth cohort effect: evidence of a continuous decrease of infection rates in childhood. Am J Gastroenterol 92(9):1480–1482

    PubMed  CAS  Google Scholar 

  20. Haruma K, Okamoto S, Kawaguchi H, Gotoh T, Kamada T, Yoshihara M, Sumii K, Kajiyama G (1997) Reduced incidence of Helicobacter pylori infection in young Japanese persons between the 1970s and the 1990s. J Clin Gastroenterol 25(4):583–586

    Article  PubMed  CAS  Google Scholar 

  21. Parsonnet J, Blaser MJ, Perez-Perez GI, Hargrett-Bean N, Tauxe RV (1992) Symptoms and risk factors of Helicobacter pylori infection in a cohort of epidemiologists. Gastroenterology 102(1):41–46 [pii]:S0016508592000362

    PubMed  CAS  Google Scholar 

  22. Telaranta-Keerie A, Kara R, Paloheimo L, Harkonen M, Sipponen P (2010) Prevalence of undiagnosed advanced atrophic corpus gastritis in Finland: an observational study among 4,256 volunteers without specific complaints. Scand J Gastroenterol 45(9):1036–1041. doi:10.3109/00365521.2010.487918

    Article  PubMed  Google Scholar 

  23. Rees K, Stowe R, Patel S, Ives N, Breen K, Clarke CE, Ben-Shlomo Y (2011) Helicobacter pylori eradication for Parkinson’s disease. Cochrane Database Syst Rev (11):CD008453. doi:10.1002/14651858.CD008453.pub2

  24. Hoehn MM, Yahr MD (1967) Parkinsonism: onset, progression and mortality. Neurology 17(5):427–442

    Article  PubMed  CAS  Google Scholar 

  25. Movement Disorder Society Task Force on Rating Scales for Parkinson’s Disease (2003) The Unified Parkinson’s Disease Rating Scale (UPDRS): status and recommendations. Mov Disord 18(7):738–750. doi:10.1002/mds.10473

    Article  Google Scholar 

  26. Stacy MA, Murphy JM, Greeley DR, Stewart RM, Murck H, Meng X (2008) The sensitivity and specificity of the 9-item Wearing-off Questionnaire. Parkinsonism Relat Disord 14(3):205–212. doi:10.1016/j.parkreldis.2007.07.013

    Article  PubMed  CAS  Google Scholar 

  27. Tomlinson CL, Stowe R, Patel S, Rick C, Gray R, Clarke CE (2010) Systematic review of levodopa dose equivalency reporting in Parkinson’s disease. Mov Disord 25(15):2649–2653. doi:10.1002/mds.23429

    Article  PubMed  Google Scholar 

  28. Evrengul H, Tanriverdi H, Kuru O, Enli Y, Yuksel D, Kilic A, Kaftan A, Kirac S, Kilic M (2007) Elevated homocysteine levels in patients with slow coronary flow: relationship with Helicobacter pylori infection. Helicobacter 12(4):298–305. doi:10.1111/j.1523-5378.2007.00505.x

    Article  PubMed  CAS  Google Scholar 

  29. Hu XW, Qin SM, Li D, Hu LF, Liu CF (2013) Elevated homocysteine levels in levodopa-treated idiopathic Parkinson’s disease: a meta-analysis. Acta Neurol Scand 128(2):73–82. doi:10.1111/ane.12106

    Article  PubMed  CAS  Google Scholar 

  30. Pietroiusti A, Galante A, Magrini A, Bergamaschi A (2008) Helicobacter pylori interference with micronutrients and orally administered drugs: a new mechanism explaining its role in extragastric disorders. Mini Rev Med Chem 8(2):135–141

    Article  PubMed  CAS  Google Scholar 

  31. Marino MC, de Oliveira CA, Rocha AM, Rocha GA, Clementino NC, Antunes LF, Oliveira RA, Martins AS, Del Puerto HL, D’Almeida V, Galdieri L, Pedroso ER, Cabral MM, Nogueira AM, Queiroz DM (2007) Long-term effect of Helicobacter pylori eradication on plasma homocysteine in elderly patients with cobalamin deficiency. Gut 56(4):469–474. doi:10.1136/gut.2006.095125

    Article  PubMed  CAS  Google Scholar 

  32. Sekhon J (2011) Multivariate and propensity score matching software with automated balance optimization: the matching package for R. J Stat Softw 42:1–52

    Google Scholar 

  33. Fahn S, Oakes D, Shoulson I, Kieburtz K, Rudolph A, Lang A, Olanow CW, Tanner C, Marek K (2004) Levodopa and the progression of Parkinson’s disease. N Engl J Med 351(24):2498–2508. doi:10.1056/NEJMoa033447

    Article  PubMed  CAS  Google Scholar 

  34. Stocchi F, Rascol O, Kieburtz K, Poewe W, Jankovic J, Tolosa E, Barone P, Lang AE, Olanow CW (2010) Initiating levodopa/carbidopa therapy with and without entacapone in early Parkinson disease: the STRIDE-PD study. Ann Neurol 68(1):18–27. doi:10.1002/ana.22060

    Article  PubMed  CAS  Google Scholar 

  35. Nyholm D, Askmark H, Aquilonius SM (2011) Stalevo reduction in dyskinesia evaluation in Parkinson’s disease results were expected from a pharmacokinetic viewpoint. Ann Neurol 69(2):424. doi:10.1002/ana.22257 author reply 425

    Article  PubMed  Google Scholar 

  36. Wong WM, Lam SK, Lai KC, Chu KM, Xia HH, Wong KW, Cheung KL, Lin SK, Wong BC (2003) A rapid-release 50-mg tablet-based 13C-urea breath test for the diagnosis of Helicobacter pylori infection. Aliment Pharmacol Ther 17(2):253–257 [pii]:1417

    Article  PubMed  CAS  Google Scholar 

  37. Kokkola A, Kosunen TU, Puolakkainen P, Sipponen P, Harkonen M, Laxen F, Virtamo J, Haapiainen R, Rautelin H (2003) Spontaneous disappearance of Helicobacter pylori antibodies in patients with advanced atrophic corpus gastritis. APMIS 111(6):619–624

    Article  PubMed  Google Scholar 

  38. Salomaa-Rasanen A, Kosunen TU, Mattila J, Sarna S, Rautelin H (2004) Age-dependent accuracy of Helicobacter pylori antibody assays for adults, with special emphasis on atrophic gastritis. Clin Diagn Lab Immunol 11(6):1185–1188. doi:10.1128/CDLI.11.6.1185-1188.2004

    PubMed  CAS  Google Scholar 

  39. Graham DY, Opekun AR, Yamaoka Y, Osato MS, el-Zimaity HM (2003) Early events in proton pump inhibitor-associated exacerbation of corpus gastritis. Aliment Pharmacol Ther 17(2):193–200

    Article  PubMed  CAS  Google Scholar 

  40. Murakami K, Sato R, Okimoto T, Watanabe K, Nasu M, Fujioka T, Kodama M, Kagawa J (2003) Influence of anti-ulcer drugs used in Japan on the result of 13C-urea breath test for the diagnosis of Helicobacter pylori infection. J Gastroenterol 38(10):937–941. doi:10.1007/s00535-003-1176-x

    Article  PubMed  CAS  Google Scholar 

  41. Varis K, Sipponen P, Laxen F, Samloff IM, Huttunen JK, Taylor PR, Heinonen OP, Albanes D, Sande N, Virtamo J, Harkonen M (2000) Implications of serum pepsinogen I in early endoscopic diagnosis of gastric cancer and dysplasia. Helsinki Gastritis Study Group. Scand J Gastroenterol 35(9):950–956

    Article  PubMed  CAS  Google Scholar 

  42. Drake IM, Mapstone NP, Schorah CJ, White KL, Chalmers DM, Dixon MF, Axon AT (1998) Reactive oxygen species activity and lipid peroxidation in Helicobacter pylori associated gastritis: relation to gastric mucosal ascorbic acid concentrations and effect of H pylori eradication. Gut 42(6):768–771

    Article  PubMed  CAS  Google Scholar 

  43. Lee WY, Yoon WT, Shin HY, Jeon SH, Rhee PL (2008) Helicobacter pylori infection and motor fluctuations in patients with Parkinson’s disease. Mov Disord 23(12):1696–1700. doi:10.1002/mds.22190

    Article  PubMed  Google Scholar 

  44. Salim AS (1993) The relationship between Helicobacter pylori and oxygen-derived free radicals in the mechanism of duodenal ulceration. Intern Med 32(5):359–364

    Article  PubMed  CAS  Google Scholar 

  45. Lahner E, Annibale B, Delle Fave G (2009) Systematic review: Helicobacter pylori infection and impaired drug absorption. Aliment Pharmacol Ther 29(4):379–386. doi:10.1111/j.1365-2036.2008.03906.x

    Article  PubMed  CAS  Google Scholar 

  46. Dixon M (1996) Pathological consequences of Helicobacter pylori infection. Scand J Gastroenterol Suppl 215:21

    PubMed  CAS  Google Scholar 

Download references

Acknowledgments

Kibion AB, Solvay Pharmaceuticals, and Uppsala University are acknowledged for support. The authors thank Marcus Thuresson, Statisticon AB, Uppsala, Sweden, for statistical analyses. The Diabact UBT kits including analyses were provided by Kibion AB. A grant for laboratory analyses was provided by Solvay Pharmaceuticals. A postdoc grant from Uppsala University was used.

Author information

Authors and Affiliations

  1. NeuroCenter Saint Göran Hospital, Stockholm, Sweden

    Karl-Erik Rahne

  2. Department of Neuroscience, Neurology, Uppsala University, 75185, Uppsala, Sweden

    Carl Tagesson & Dag Nyholm

Authors
  1. Karl-Erik Rahne
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Carl Tagesson
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Dag Nyholm
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Dag Nyholm.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Rahne, KE., Tagesson, C. & Nyholm, D. Motor fluctuations and Helicobacter pylori in Parkinson’s disease. J Neurol 260, 2974–2980 (2013). https://doi.org/10.1007/s00415-013-7089-6

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00415-013-7089-6

Keywords

Search

Navigation